hVIVO Regulatory News (HVO)

HVIVO PLC

("hVIVO" or the "Company")

Exercise of Share Options

London, UK, 21 March 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, an application has been made to the London Stock Exchange for the admission of 644,600 new ordinary shares of 5.0p each (the "New Ordinary Shares") following an exercise of options by a former employee of the Company.

Admission to trading on AIM of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 26 March 2019.

Following Admission, the total number of ordinary shares with voting rights in issue will be 82,941,565, and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

For further information please contact:

Notes to Editors:

hVIVO plc ("hVIVO") is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development.